Literature DB >> 33439360

Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients.

Jean-Rémi Lavillegrand1,2, Marc Garnier2,3, Agathe Spaeth4, Nathalie Mario4, Geoffroy Hariri1,2, Antoine Pilon4, Enora Berti2,5, Fabienne Fieux3, Sara Thietart1, Tomas Urbina1,2, Matthieu Turpin2,5, Lucie Darrivere3, Muriel Fartoukh2,5, Franck Verdonk3, Guillaume Dumas1, Alain Tedgui6, Bertrand Guidet1,2, Eric Maury1,2, Yannick Chantran7, Guillaume Voiriot2,5, Hafid Ait-Oufella8,9,10.   

Abstract

BACKGROUND: SARS coronavirus 2 (SARS-CoV-2) is responsible for high morbidity and mortality worldwide, mostly due to the exacerbated inflammatory response observed in critically ill patients. However, little is known about the kinetics of the systemic immune response and its association with survival in SARS-CoV-2+ patients admitted in ICU. We aimed to compare the immuno-inflammatory features according to organ failure severity and in-ICU mortality.
METHODS: Six-week multicentre study (N = 3) including SARS-CoV-2+ patients admitted in ICU. Analysis of plasma biomarkers at days 0 and 3-4 according to organ failure worsening (increase in SOFA score) and 60-day mortality.
RESULTS: 101 patients were included. Patients had severe respiratory diseases with PaO2/FiO2 of 155 [111-251] mmHg), SAPS II of 37 [31-45] and SOFA score of 4 [3-7]. Eighty-three patients (83%) required endotracheal intubation/mechanical ventilation and among them, 64% were treated with prone position. IL-1β was barely detectable. Baseline IL-6 levels positively correlated with organ failure severity. Baseline IL-6 and CRP levels were significantly higher in patients in the worsening group than in the non-worsening group (278 [70-622] vs. 71 [29-153] pg/mL, P < 0.01; and 178 [100-295] vs. 100 [37-213] mg/L, P < 0.05, respectively). Baseline IL-6 and CRP levels were significantly higher in non-survivors compared to survivors but fibrinogen levels and lymphocyte counts were not different between groups. After adjustment on SOFA score and time from symptom onset to first dosage, IL-6 and CRP remained significantly associated with mortality. IL-6 changes between Day 0 and Day 3-4 were not different according to the outcome. A contrario, kinetics of CRP and lymphocyte count were different between survivors and non-survivors.
CONCLUSIONS: In SARS-CoV-2+ patients admitted in ICU, a systemic pro-inflammatory signature was associated with clinical worsening and 60-day mortality.

Entities:  

Keywords:  Covid-19; Cytokine; Inflammation; Outcome; SARS-CoV-2

Year:  2021        PMID: 33439360      PMCID: PMC7804215          DOI: 10.1186/s13613-020-00798-x

Source DB:  PubMed          Journal:  Ann Intensive Care        ISSN: 2110-5820            Impact factor:   6.925


  11 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Authors:  Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

3.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.

Authors:  Barnaby Edward Young; Sean Wei Xiang Ong; Shirin Kalimuddin; Jenny G Low; Seow Yen Tan; Jiashen Loh; Oon-Tek Ng; Kalisvar Marimuthu; Li Wei Ang; Tze Minn Mak; Sok Kiang Lau; Danielle E Anderson; Kian Sing Chan; Thean Yen Tan; Tong Yong Ng; Lin Cui; Zubaidah Said; Lalitha Kurupatham; Mark I-Cheng Chen; Monica Chan; Shawn Vasoo; Lin-Fa Wang; Boon Huan Tan; Raymond Tzer Pin Lin; Vernon Jian Ming Lee; Yee-Sin Leo; David Chien Lye
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

4.  Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene.

Authors:  B Weinhold; U Rüther
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

5.  Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.

Authors:  Muhammad Aziz; Hossein Haghbin; Emad Abu Sitta; Yusuf Nawras; Rawish Fatima; Sachit Sharma; Wade Lee-Smith; Joan Duggan; Joel A Kammeyer; Jennifer Hanrahan; Ragheb Assaly
Journal:  J Med Virol       Date:  2020-09-28       Impact factor: 2.327

Review 6.  Role of C-Reactive Protein at Sites of Inflammation and Infection.

Authors:  Nicola R Sproston; Jason J Ashworth
Journal:  Front Immunol       Date:  2018-04-13       Impact factor: 7.561

7.  IL-6-based mortality risk model for hospitalized patients with COVID-19.

Authors:  Rocio Laguna-Goya; Alberto Utrero-Rico; Paloma Talayero; Maria Lasa-Lazaro; Angel Ramirez-Fernandez; Laura Naranjo; Alejandro Segura-Tudela; Oscar Cabrera-Marante; Edgar Rodriguez de Frias; Rocio Garcia-Garcia; Mario Fernández-Ruiz; Jose Maria Aguado; Joaquin Martinez-Lopez; Elena Ana Lopez; Mercedes Catalan; Antonio Serrano; Estela Paz-Artal
Journal:  J Allergy Clin Immunol       Date:  2020-07-22       Impact factor: 10.793

8.  Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.

Authors:  Saeed K Alzghari; Valerie S Acuña
Journal:  J Clin Virol       Date:  2020-04-21       Impact factor: 3.168

9.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.

Authors:  Corrado Lodigiani; Giacomo Iapichino; Luca Carenzo; Maurizio Cecconi; Paola Ferrazzi; Tim Sebastian; Nils Kucher; Jan-Dirk Studt; Clara Sacco; Alexia Bertuzzi; Maria Teresa Sandri; Stefano Barco
Journal:  Thromb Res       Date:  2020-04-23       Impact factor: 3.944

10.  Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Authors:  Daniel E Leisman; Lukas Ronner; Rachel Pinotti; Matthew D Taylor; Pratik Sinha; Carolyn S Calfee; Alexandre V Hirayama; Fiore Mastroiani; Cameron J Turtle; Michael O Harhay; Matthieu Legrand; Clifford S Deutschman
Journal:  Lancet Respir Med       Date:  2020-10-16       Impact factor: 30.700

View more
  20 in total

1.  Evaluation of C4b as an adjunct marker in symptomatic RT-PCR negative Covid-19 cases.

Authors:  Bandana Kumari; Krishnan Hajela; Asgar Ali; Abhay Kumar Sharma; Rajesh Kumar Yadav; Alok Ranjan; Rathish Nair; Shreekant Bharti; Satish Dipankar; Prabhat Kumar Singh; Sadhana Sharma
Journal:  Indian J Clin Biochem       Date:  2022-06-20

2.  Clinical utility of inflammatory biomarkers in COVID-19 in direct comparison to other respiratory infections-A prospective cohort study.

Authors:  Maurin Lampart; Núria Zellweger; Stefano Bassetti; Sarah Tschudin-Sutter; Katharina M Rentsch; Martin Siegemund; Roland Bingisser; Stefan Osswald; Gabriela M Kuster; Raphael Twerenbold
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

3.  Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients.

Authors:  María Trujillo-Rodriguez; Esperanza Muñoz-Muela; Ana Serna-Gallego; Juan Manuel Praena-Fernández; Alberto Pérez-Gómez; Carmen Gasca-Capote; Joana Vitallé; Joaquim Peraire; Zaira R Palacios-Baena; Jorge Julio Cabrera; Ezequiel Ruiz-Mateos; Eva Poveda; Luis Eduardo López-Cortés; Anna Rull; Alicia Gutierrez-Valencia; Luis Fernando López-Cortés
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

4.  Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Michael J Peluso; Scott Lu; Alex F Tang; Matthew S Durstenfeld; Hsi-En Ho; Sarah A Goldberg; Carrie A Forman; Sadie E Munter; Rebecca Hoh; Viva Tai; Ahmed Chenna; Brandon C Yee; John W Winslow; Christos J Petropoulos; Bryan Greenhouse; Peter W Hunt; Priscilla Y Hsue; Jeffrey N Martin; J Daniel Kelly; David V Glidden; Steven G Deeks; Timothy J Henrich
Journal:  J Infect Dis       Date:  2021-12-01       Impact factor: 7.759

5.  Correction to: Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: infammatory response of SARS-CoV-2 patients.

Authors:  Jean-Rémi Lavillegrand; Marc Garnier; Agathe Spaeth; Nathalie Mario; Geofroy Hariri; Antoine Pilon; Enora Berti; Fabienne Fieux; Sara Thietart; Tomas Urbina; Matthieu Turpin; Lucie Darrivere; Muriel Fartoukh; Franck Verdonk; Guillaume Dumas; Alain Tedgui; Bertrand Guidet; Eric Maury; Yannick Chantran; Guillaume Voiriot; Hafd Ait-Oufella
Journal:  Ann Intensive Care       Date:  2021-06-09       Impact factor: 6.925

Review 6.  Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.

Authors:  Yongjun Sui; Yonas Bekele; Jay A Berzofsky
Journal:  Pathogens       Date:  2021-01-30

7.  LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL.

Authors:  Zelalem Temesgen; Charles D Burger; Jason Baker; Christopher Polk; Claudia Libertin; Colleen Kelley; Vincent C Marconi; Robert Orenstein; Cameron Durrant; Dale Chappell; Omar Ahmed; Gabrielle Chappell; Andrew D Badley
Journal:  medRxiv       Date:  2021-05-05

Review 8.  Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions.

Authors:  Michael J Peluso; Joanna Donatelli; Timothy J Henrich
Journal:  Transl Res       Date:  2021-11-12       Impact factor: 7.012

Review 9.  Insights into the virologic and immunologic features of SARS-COV-2.

Authors:  Ceylan Polat; Koray Ergunay
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

10.  Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units.

Authors:  Alberto Zanella; Gaetano Florio; Massimo Antonelli; Giacomo Bellani; Angela Berselli; Tiziana Bove; Luca Cabrini; Eleonora Carlesso; Gian Paolo Castelli; Maurizio Cecconi; Giuseppe Citerio; Irene Coloretti; Daniele Corti; Francesca Dalla Corte; Edoardo De Robertis; Giuseppe Foti; Roberto Fumagalli; Massimo Girardis; Riccardo Giudici; Lorenzo Guiotto; Thomas Langer; Lucia Mirabella; Daniela Pasero; Alessandro Protti; Marco V Ranieri; Roberto Rona; Luigia Scudeller; Paolo Severgnini; Savino Spadaro; Nino Stocchetti; Martina Viganò; Antonio Pesenti; Giacomo Grasselli
Journal:  Intensive Care Med       Date:  2021-08-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.